Delphi Panel Consensus Regarding Current Clinical Practice Management Options for Demodex blepharitis

Marjan Farid,1 Brandon D Ayres,2 Eric Donnenfeld,3 Ian Benjamin Gaddie,4 Preeya K Gupta,5 Edward Holland,6 Richard Lindstrom,7 Stephen C Pflugfelder,8 Paul M Karpecki,9 Kelly K Nichols,10 Christopher E Starr,11 Elizabeth Yeu12 1Gavin Herbert Eye Institute, UC-Irvine, Irvine, CA, USA; 2Wills Eye Hosp...

Full description

Bibliographic Details
Main Authors: Farid M, Ayres BD, Donnenfeld E, Gaddie IB, Gupta PK, Holland E, Lindstrom R, Pflugfelder SC, Karpecki PM, Nichols KK, Starr CE, Yeu E
Format: Article
Language:English
Published: Dove Medical Press 2023-02-01
Series:Clinical Ophthalmology
Subjects:
Online Access:https://www.dovepress.com/delphi-panel-consensus-regarding-current-clinical-practice-management--peer-reviewed-fulltext-article-OPTH
_version_ 1811162870624288768
author Farid M
Ayres BD
Donnenfeld E
Gaddie IB
Gupta PK
Holland E
Lindstrom R
Pflugfelder SC
Karpecki PM
Nichols KK
Starr CE
Yeu E
author_facet Farid M
Ayres BD
Donnenfeld E
Gaddie IB
Gupta PK
Holland E
Lindstrom R
Pflugfelder SC
Karpecki PM
Nichols KK
Starr CE
Yeu E
author_sort Farid M
collection DOAJ
description Marjan Farid,1 Brandon D Ayres,2 Eric Donnenfeld,3 Ian Benjamin Gaddie,4 Preeya K Gupta,5 Edward Holland,6 Richard Lindstrom,7 Stephen C Pflugfelder,8 Paul M Karpecki,9 Kelly K Nichols,10 Christopher E Starr,11 Elizabeth Yeu12 1Gavin Herbert Eye Institute, UC-Irvine, Irvine, CA, USA; 2Wills Eye Hospital, Philadelphia, PA, USA; 3Ophthalmic Consultants of Long Island, Long Island, NY, USA; 4Gaddie Eye Centers, Louisville, KY, USA; 5Triangle Eye Consultants, Raleigh, NC and Tulane University, New Orleans, LA, USA; 6University of Cincinnati, Cincinnati, OH, USA; 7University of Minnesota, Minneapolis, MN, USA; 8Baylor College of Medicine, Houston, TX, USA; 9Kentucky Eye Institute, Lexington, KY, USA; 10University of Alabama at Birmingham, School of Optometry, Birmingham, AL, USA; 11Weill Cornell Medicine, New York, NY, USA; 12Virginia Eye Consultants, Norfolk, VA, USACorrespondence: Marjan Farid, University of California, 850 Health Sciences Road, Mail Code: 4375, Irvine, CA, 92697, USA, Tel +1 949 824-0327, Email mfarid@uci.eduPurpose: To obtain consensus on Demodex blepharitis (DB) treatment using a modified Delphi panel process.Methods: Literature search identified gaps in knowledge surrounding treatment of DB. Twelve ocular surface disease experts comprised the Demodex Expert Panel on Treatment and Eyelid Health (DEPTH). They completed a live roundtable discussion in addition to 3 surveys consisting of scaled, open-ended, true/false, and multiple-choice questions pertaining to the treatment of DB. Consensus for scaled questions using a 1 to 9 Likert scale was predefined as median scores of 7– 9 and 1– 3. For other question types, consensus was achieved when 8 of 12 panelists agreed.Results: The experts agreed that an effective therapeutic agent for treatment of DB would likely decrease the necessity of mechanical intervention, such as lid scrubs or blepharoexfoliation (Median = 8.5; Range 2– 9). When treating DB, panelists believed that collarettes serve as a surrogate for mites, and that eliminating or reducing collarettes should be the main clinical goal of treatment (Median = 8; Range 7– 9). The panelists would treat patients with at least 10 collarettes, regardless of other signs or symptoms and agreed that DB can be cured, but there is always the possibility for a reinfestation (n = 12). There was also consensus that collarettes, and therefore mites, are the primary treatment target and the way by which clinicians can monitor patient response to therapy (Median = 8; Range 7– 9).Conclusion: Expert panelists achieved consensus on key facets of DB treatment. Specifically, there was consensus that collarettes are pathognomonic for DB, that DB patients with > 10 collarettes should be treated even in the absence of symptoms, and that treatment efficacy can be tracked by collarette resolution. By increasing awareness about DB, understanding the goals of and monitoring treatment efficacy, patients will receive better care and, ultimately, better clinical outcomes.Keywords: collarettes, cylindrical dandruff, ocular surface disease, eyelid disease
first_indexed 2024-04-10T06:37:19Z
format Article
id doaj.art-5e5be5fb25ce4bfc9b18c388b6c10f59
institution Directory Open Access Journal
issn 1177-5483
language English
last_indexed 2024-04-10T06:37:19Z
publishDate 2023-02-01
publisher Dove Medical Press
record_format Article
series Clinical Ophthalmology
spelling doaj.art-5e5be5fb25ce4bfc9b18c388b6c10f592023-02-28T18:02:43ZengDove Medical PressClinical Ophthalmology1177-54832023-02-01Volume 1766767981892Delphi Panel Consensus Regarding Current Clinical Practice Management Options for Demodex blepharitisFarid MAyres BDDonnenfeld EGaddie IBGupta PKHolland ELindstrom RPflugfelder SCKarpecki PMNichols KKStarr CEYeu EMarjan Farid,1 Brandon D Ayres,2 Eric Donnenfeld,3 Ian Benjamin Gaddie,4 Preeya K Gupta,5 Edward Holland,6 Richard Lindstrom,7 Stephen C Pflugfelder,8 Paul M Karpecki,9 Kelly K Nichols,10 Christopher E Starr,11 Elizabeth Yeu12 1Gavin Herbert Eye Institute, UC-Irvine, Irvine, CA, USA; 2Wills Eye Hospital, Philadelphia, PA, USA; 3Ophthalmic Consultants of Long Island, Long Island, NY, USA; 4Gaddie Eye Centers, Louisville, KY, USA; 5Triangle Eye Consultants, Raleigh, NC and Tulane University, New Orleans, LA, USA; 6University of Cincinnati, Cincinnati, OH, USA; 7University of Minnesota, Minneapolis, MN, USA; 8Baylor College of Medicine, Houston, TX, USA; 9Kentucky Eye Institute, Lexington, KY, USA; 10University of Alabama at Birmingham, School of Optometry, Birmingham, AL, USA; 11Weill Cornell Medicine, New York, NY, USA; 12Virginia Eye Consultants, Norfolk, VA, USACorrespondence: Marjan Farid, University of California, 850 Health Sciences Road, Mail Code: 4375, Irvine, CA, 92697, USA, Tel +1 949 824-0327, Email mfarid@uci.eduPurpose: To obtain consensus on Demodex blepharitis (DB) treatment using a modified Delphi panel process.Methods: Literature search identified gaps in knowledge surrounding treatment of DB. Twelve ocular surface disease experts comprised the Demodex Expert Panel on Treatment and Eyelid Health (DEPTH). They completed a live roundtable discussion in addition to 3 surveys consisting of scaled, open-ended, true/false, and multiple-choice questions pertaining to the treatment of DB. Consensus for scaled questions using a 1 to 9 Likert scale was predefined as median scores of 7– 9 and 1– 3. For other question types, consensus was achieved when 8 of 12 panelists agreed.Results: The experts agreed that an effective therapeutic agent for treatment of DB would likely decrease the necessity of mechanical intervention, such as lid scrubs or blepharoexfoliation (Median = 8.5; Range 2– 9). When treating DB, panelists believed that collarettes serve as a surrogate for mites, and that eliminating or reducing collarettes should be the main clinical goal of treatment (Median = 8; Range 7– 9). The panelists would treat patients with at least 10 collarettes, regardless of other signs or symptoms and agreed that DB can be cured, but there is always the possibility for a reinfestation (n = 12). There was also consensus that collarettes, and therefore mites, are the primary treatment target and the way by which clinicians can monitor patient response to therapy (Median = 8; Range 7– 9).Conclusion: Expert panelists achieved consensus on key facets of DB treatment. Specifically, there was consensus that collarettes are pathognomonic for DB, that DB patients with > 10 collarettes should be treated even in the absence of symptoms, and that treatment efficacy can be tracked by collarette resolution. By increasing awareness about DB, understanding the goals of and monitoring treatment efficacy, patients will receive better care and, ultimately, better clinical outcomes.Keywords: collarettes, cylindrical dandruff, ocular surface disease, eyelid diseasehttps://www.dovepress.com/delphi-panel-consensus-regarding-current-clinical-practice-management--peer-reviewed-fulltext-article-OPTHcollarettescylindrical dandruffocular surface diseaseeyelid disease
spellingShingle Farid M
Ayres BD
Donnenfeld E
Gaddie IB
Gupta PK
Holland E
Lindstrom R
Pflugfelder SC
Karpecki PM
Nichols KK
Starr CE
Yeu E
Delphi Panel Consensus Regarding Current Clinical Practice Management Options for Demodex blepharitis
Clinical Ophthalmology
collarettes
cylindrical dandruff
ocular surface disease
eyelid disease
title Delphi Panel Consensus Regarding Current Clinical Practice Management Options for Demodex blepharitis
title_full Delphi Panel Consensus Regarding Current Clinical Practice Management Options for Demodex blepharitis
title_fullStr Delphi Panel Consensus Regarding Current Clinical Practice Management Options for Demodex blepharitis
title_full_unstemmed Delphi Panel Consensus Regarding Current Clinical Practice Management Options for Demodex blepharitis
title_short Delphi Panel Consensus Regarding Current Clinical Practice Management Options for Demodex blepharitis
title_sort delphi panel consensus regarding current clinical practice management options for demodex blepharitis
topic collarettes
cylindrical dandruff
ocular surface disease
eyelid disease
url https://www.dovepress.com/delphi-panel-consensus-regarding-current-clinical-practice-management--peer-reviewed-fulltext-article-OPTH
work_keys_str_mv AT faridm delphipanelconsensusregardingcurrentclinicalpracticemanagementoptionsfordemodexblepharitis
AT ayresbd delphipanelconsensusregardingcurrentclinicalpracticemanagementoptionsfordemodexblepharitis
AT donnenfelde delphipanelconsensusregardingcurrentclinicalpracticemanagementoptionsfordemodexblepharitis
AT gaddieib delphipanelconsensusregardingcurrentclinicalpracticemanagementoptionsfordemodexblepharitis
AT guptapk delphipanelconsensusregardingcurrentclinicalpracticemanagementoptionsfordemodexblepharitis
AT hollande delphipanelconsensusregardingcurrentclinicalpracticemanagementoptionsfordemodexblepharitis
AT lindstromr delphipanelconsensusregardingcurrentclinicalpracticemanagementoptionsfordemodexblepharitis
AT pflugfeldersc delphipanelconsensusregardingcurrentclinicalpracticemanagementoptionsfordemodexblepharitis
AT karpeckipm delphipanelconsensusregardingcurrentclinicalpracticemanagementoptionsfordemodexblepharitis
AT nicholskk delphipanelconsensusregardingcurrentclinicalpracticemanagementoptionsfordemodexblepharitis
AT starrce delphipanelconsensusregardingcurrentclinicalpracticemanagementoptionsfordemodexblepharitis
AT yeue delphipanelconsensusregardingcurrentclinicalpracticemanagementoptionsfordemodexblepharitis